+31 50 3137464 info@sulfateqbv.com

Kidney Week 2017

The international kidney week is right around the corner. From 31 October until 5 November 2017 more than 13.000 kidney professionals from across the globe will come to New Orleans to exchange knowledge about the fight against kidney disease. Acute kidney injury (AKI)...

New publication SUL-121 compound

In the range of compounds for protecting organs from Sulfateq a new paper is published. We are proud to announce that Dr. L.E. (Leo) Deelman (UMCG) has published his paper on the protective effects of our SUL-121 compound in diabetes. SUL-121 preserves endothelial...

Dr. Rob Henning on hibernation (BBC2)

Tonight (11 September 2017) please tune in to BBC2. At 22:00 (Dutch time), Professor Rob Henning of the UMCG discusses the need for human hibernation. In this episode of “The search for a new world” Christophe meets anaesthesiologist Dr. Rob Henning, who...

Sepsis: a new application for the SUL-compounds?

Sulfateq B.V. is dedicated to developing new drugs for several diseases: Acute Kidney Injury (AKI), Chronic Obstructive Pulmonary Disease (COPD),  Type II Diabetes (T2D) and obesity. We can now proudly announce that the SUL-compounds are being tested in sepsis, which...

BIO-Europe 2016 – Cologne

From 7 till 9 November 2016 we will be attending BIO-Europe 2016 in Cologne (Germany). BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. Our CEO Kees van der Graaf will be present on these days to talk about business...